Price
$7.11
Decreased by -3.92%
Dollar Volume (20D)
14.09 M
ADR%
14.26
Earnings Report Date (estimate)
Mar 21, 24
Shares Float
42.94 M
Shares Outstanding
77.23 M
Shares Short
3.87 M
Market Cap.
571.5 M
Beta
1.53
Price / Earnings
N/A
20D Range
2.58 9.39
50D Range
1.85 9.39
200D Range
1.18 9.39
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 9, 23 -0.47
Decreased by -17.5%
-0.26
Decreased by -80.77%
Aug 10, 23 -0.37
Increased by +53.75%
-0.26
Decreased by -42.31%
May 11, 23 -0.18
Increased by +79.55%
-0.31
Increased by +41.94%
Mar 23, 23 -0.16
Increased by +84.62%
-0.46
Increased by +65.22%
Nov 9, 22 -0.4
Increased by +63.3%
-0.48
Increased by +16.67%
Aug 12, 22 -0.8
Increased by +19.19%
-0.78
Decreased by -2.56%
May 12, 22 -0.88
Increased by +12%
-0.83
Decreased by -6.02%
Mar 10, 22 -1.04
Increased by +1.89%
-1.25
Increased by +16.8%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 0
Decreased by N/A%
-42.37 M
Decreased by -125.25%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0
Decreased by N/A%
-29.58 M
Increased by +13.85%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 10.66 M
Increased by +N/A%
-9.42 M
Increased by +59.18%
Decreased by -88.33%
Decreased by N/A%
Dec 31, 22 0
Decreased by N/A%
-5.82 M
Increased by +78.58%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0
Decreased by N/A%
-18.81 M
Increased by +33.81%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0
Decreased by N/A%
-34.33 M
Decreased by -32.92%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0
Decreased by N/A%
-23.07 M
Increased by +4.61%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0
Decreased by N/A%
-27.16 M
Decreased by -14.65%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States. Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.